STAT+: ‘I’m still here’: Before Alzheimer’s, he prided himself on his intellect
Truck. Banana. Violin. Desk. Green. Sitting behind her desk in an examining room, the neurologist…
Category: Alzheimer’s
STAT+: Drug aimed at strengthening neurons to treat Alzheimer’s fails in trial
A dark horse effort to treat Alzheimer’s disease, already marred by a data manipulation scandal,…
Opinion: Who should get to see the neurologist first: the sick or the at-risk?
Once a year, Jessi Keavney goes to see her neurologist. During the visit, the doctor asks if…
Alzheimer’s drug may raise the risk of brain bleed in patients with Down syndrome
A year ago, after much fanfare and controversy, the Food and Drug Administration approved Eisai…
Opinion: Phasing out the ‘D-word’
As I roamed the meeting rooms and halls of the Alzheimer’s Association International Conference in…
Blood tests for Alzheimer’s diagnosis were 91% accurate in new study
New blood tests could help doctors diagnose Alzheimer’s disease faster and more accurately, researchers reported Sunday –…
Opinion: Survey: Neurologists split on prescribing new Alzheimer’s treatments
As more than 7,500 clinicians and researchers converge in Philadelphia for the Alzheimer’s Association International…
Listen: JD Vance’s biotech ties, Cassava resignations, and insulin shortages
What relation does JD Vance have with Vivek Ramaswamy? Do pharma companies have a moral…
STAT+: New study bolsters evidence rare genetic mutation can delay early Alzheimer’s
For members of a large extended Colombian family, an early Alzheimer’s diagnosis is practically a…
How a Baltimore neuroscience study is rewriting Black America’s relationship with medical research
Priscilla Agnew-Hines will never be able to forget that day in early 2020. On March…
Listen: Duchenne gene therapy setback, Alzheimer’s drug endorsement & why a STAT reporter buys weed (for journalism)
On this week’s episode of “The Readout LOUD,” our STAT colleague Nicholas Florko joins us…
STAT+: FDA advisers unanimously recommend approval of Eli Lilly’s Alzheimer’s disease treatment
Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval…
Opinion: Outdated Medicare rules prevent some dementia patients from getting the medications they need
Memory loss is the most obvious symptom of Alzheimer’s disease. But for the more than…
STAT+: Getting Alzheimer’s treatment to those who need it poses particular challenges
A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts…
STAT Virtual Event | Navigating a New Era in Alzheimer’s Treatment
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET….
Vertex starts gene therapy Casgevy in five patients
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Biogen’s Alzheimer’s drug launch on ‘steady pace’ as logistical hurdles recede
Biogen on Wednesday reported first-quarter earnings that beat Wall Street expectations largely on reduced expenses….
Medicare expects a big spike in spending on Leqembi
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money…
Gas prices are hurting biotech
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Medicare expects to spend $3.5 billion on new Alzheimer’s drug in 2025
Medicare for the first time has estimated that a new Alzheimer’s treatment could cost the…
Preventing the weaponization of AI-designed proteins
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: In surprise move, FDA calls for advisory committee on Lilly’s Alzheimer’s drug
In a surprise move, the Food and Drug Administration has called for a meeting of…
STAT+: A deep dive into Applied Therapeutics’ data, and questions on Cassava’s erased data
Have you heard the news? I’m launching a weekly email newsletter starting on March 28….
STAT+: Biogen Alzheimer’s drug launch off to slow start
Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about…
Opinion: What STAT readers think about Aduhelm, CTE and the Super Bowl, and more
STAT now publishes selected Letters to the Editor received in response to First Opinion essays…
Opinion: Aduhelm was a mess — and it could happen again
Last week, Biogen announced it will cease both the study and sale of Aduhelm, its…
What makes a drug a blockbuster — or a cautionary tale?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Scientists document first-ever transmitted Alzheimer’s cases, tied to no-longer-used medical procedure
LONDON — There was something odd about these Alzheimer’s cases. Part of it was the…
STAT+: Cognito raises $35 million for Alzheimer’s treatment device, touts benefits compared to drugs
Just as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device…
Opinion: STAT readers on patient advocacy, the utility of diagnostic tests, and more
STAT now publishes selected Letters to the Editor received in response to First Opinion essays…
Opinion: Alzheimer’s drug approvals show we need a reevaluation of patient advocacy
When faced with a loved one’s progressive neurodegenerative disease, like Alzheimer’s, or your child’s rare…
Today’s biotech news roundup, in under 800 words
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Bayer’s new CEO was dealt a duo of ‘clearing events.’ Tough choices lie ahead
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Cassava pulled back the curtain on its Alzheimer’s study — and revealed insurmountable problems
Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of…
Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise
How do cancer drugs work? What makes biotech stocks go up? And why are venture…
Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Under-the-skin injection of Eisai’s Leqembi is as effective as IV infusion, new Alzheimer’s data show
A version of the Alzheimer’s disease drug Leqembi that can be given with a simpler,…
Opinion: Do dementia villages actually work? We just don’t know
Recently, dementia villages have gained popularity in Europe and Australia as an all-in-one solution to…
STAT+: Scientists have mapped the human brain in unprecedented detail. They’re just getting started
The brain remains both the body’s most important organ and its least understood. But a…
How Seth Rogen and Lauren Miller Rogen are using comedy to support Alzheimer’s care
Alzheimer’s isn’t funny. But comedy can still be a weapon in the fight against this…
How Seth Rogen and Lauren Miller Rogan are using comedy to support Alzheimer’s care
Alzheimer’s isn’t funny. But comedy can still be a weapon in the fight against this…
STAT+: Policy experts call on Medicare to ensure data from Alzheimer’s drug registries is shared publicly
More than two dozen prominent health policy experts are urging the Biden administration to ensure…
These proteins could predict dementia risk decades before symptoms, new study suggests
Can we predict the risk of dementia decades before onset? In a study published in…
STAT+: FDA removes neurologist with financial ties to Eisai and Biogen from Alzheimer’s advisory panel
The Food and Drug Administration has removed a neurologist with financial ties to Biogen and…
STAT+: Cracking an intriguing secret of centenarians: Why so few are ravaged by Alzheimer’s disease
When Herlda Senhouse looks back — way back — in time, she vividly remembers the smells…
Don’t ignore potential microbial causes of Alzheimer’s and other chronic diseases, researchers say
SAN FRANCISCO — On a day when pharma giant Eli Lilly announced positive results from…
In the whitewashed world of Alzheimer’s research, one scientist is on a quest to understand the diversity of brains
CHICAGO — When she entered the field of Alzheimer’s research a quarter century ago, Lisa…
STAT+: As FDA considers new Alzheimer’s drug, a case study details safety concerns
Investigators on Wednesday released the first detailed case report about a patient who died after…
FDA, Biogen, and an Alzheimer’s drug approval: 8 key takeaways from congressional investigation
Congressional investigators sorted through more than 500,000 pages of documents from the Food and Drug…
STAT+: ‘Rife with irregularities’: Congressional investigation reveals FDA’s approval of Aduhelm marked by secret discussions, breaches of protocol
WASHINGTON — The Food and Drug Administration’s review and approval of a controversial Alzheimer’s drug…